Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Philip V. Hassard"'
1
An Open-Label Pilot Study Using Thioguanine as a Therapeutic Alternative in Crohn's Disease Patients Resistant to 6-Mercaptopurine Therapy
Autor: Lori Y. Kam, Ernest G. Seidman, Maria T. Abreu, Philip V. Hassard, Eric A. Vasiliauskas, Marla Dubinsky, Stephan R. Targan
Publikováno v: Inflammatory Bowel Diseases. 7:181-189
Background and Aims A substantial number of patients with inflammatory bowel disease (IBD) fail to achieve a complete clinical response with 6-mercaptopurine (6-MP) and azathioprine (AZA). Inability to achieve therapeutic 6-thioguanine nucleotide (6-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd19c816e7dbbd7c9c6051ed2f0faa4
https://doi.org/10.1097/00054725-200108000-00001
Zobrazit plný text záznamu
2
Anti–tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report
Autor: Scott W. Binder, Eric A. Vasiliauskas, Viera Nelson, Philip V. Hassard
Publikováno v: Gastroenterology. 120:995-999
Behcet's disease (BD) is a multisystem immune-mediated inflammatory disorder that involves the intestine in 3%–26% of cases. Corticosteroids, 5-aminosalicylic acid derivatives, immunomodulators, and more recently thalidomide and pentoxifylline have
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38cb3da7c4b982a9d8e05efcd24cdf57
https://doi.org/10.1053/gast.2001.22556
Zobrazit plný text záznamu
3
Efficacy of Mycophenolate Mofetil in Patients Failing 6-Mercaptopurine or Azathioprine Therapy for Crohnʼs Disease
Autor: Philip V. Hassard, Eric A. Vasiliauskas, Lori Y. Kam, Stephan R. Targan, Maria T. Abreu
Publikováno v: Inflammatory Bowel Diseases. 6:16-20
Mycophenolate mofetil (MMF) is a novel immunomodulator that may be effective in the treatment of chronic active and perianal Crohn's disease (CD). The aim of this study is to assess the efficacy of MMF in CD patients who failed or were intolerant of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d164f5892a1e9feb5e96342d2e95dd55
https://doi.org/10.1097/00054725-200002000-00003
Zobrazit plný text záznamu
4
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
Autor: Philip V. Hassard, Jerome B. Zeldis, Maria T. Abreu-Martin, Stephan R. Targan, Kostas A. Papadakis, Huiying Yang, Eric A. Vasiliauskas, Lori Y. Kam
Publikováno v: Gastroenterology. 117:1278-1287
Background & Aims: Thalidomide decreases production of tumor necrosis factor α, a proinflammatory cytokine associated with Crohn's disease (CD). In this study the safety, tolerance, and efficacy of low-dose thalidomide were evaluated for treatment o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c96e77bb49fffba4238452989ab7efd
https://doi.org/10.1016/s0016-5085(99)70277-5
Zobrazit plný text záznamu
5
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
Autor: Philip V. Hassard, Lori Y. Kam, Eric A. Vasiliauskas, Stephan R. Targan, Ernest G. Seidman, Maria T. Abreu, Huiying Yang, Marla Dubinsky
Publikováno v: Gastroenterology. 122(4)
Approximately 40% of inflammatory bowel disease (IBD) patients fail to benefit from 6-mercaptopurine (6-MP)/azathioprine (AZA). Recent reports suggest 6-thioguanine nucleotide (6-TGN) levels (235) independently correlate with remission. An inverse co
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256390d23a358e4750c543a71b677e91
https://pubmed.ncbi.nlm.nih.gov/11910368
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje